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Background: We examined the mediating effects of health insurance on poverty-colon cancer care and survival
relationships and the moderating effects of poverty on health insurance-colon cancer care and survival relationships
among women and men in California.
Methods: We analyzed registry data for 3,291 women and 3,009 men diagnosed with colon cancer between 1996
and 2000 and followed until 2011 on lymph node investigation, stage at diagnosis, surgery, chemotherapy, wait
times and survival. We obtained socioeconomic data for individual residences from the 2000 census to categorize
the following neighborhoods: high poverty (30% or more poor), middle poverty (5-29% poor) and low poverty
(less than 5% poor). Primary health insurers were Medicaid, Medicare, private or none.
Results: Evidence of mediation was observed for women, but not for men. For women, the apparent effect
of poverty disappeared in the presence of payer, and the effects of all forms of health insurance seemed
strengthened. All were advantaged on 6-year survival compared to the uninsured: Medicaid (RR = 1.83), Medicare
(RR = 1.92) and private (RR = 1.83). Evidence of moderation was also only observed for women. The effects of
all forms of health insurance were stronger for women in low poverty neighborhoods: Medicaid (RR = 2.90),
Medicare (RR = 2.91) and private (RR = 2.60). For men, only main effects of poverty and payers were observed,
the advantaging effect of private insurance being largest. Across colon cancer care processes, Medicare seemed
most instrumental for women, private payers for men.
Conclusions: Health insurance substantially mediates the quality of colon cancer care and poverty seems to
make the effects of being uninsured or underinsured even worse, especially among women in the United States.
These findings are consistent with the theory that more facilitative social and economic capital is available in more
affluent neighborhoods, where women with colon cancer may be better able to absorb the indirect and direct,
but uncovered, costs of care.
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A study of cancer survival in low-income areas of
Toronto, Ontario, and Detroit, Michigan, during the
1980s found advantages among Canadians for common
cancers including colon cancer [1]. The Canadian sur-
vival advantage was systematically replicated across di-
verse low-income Canadian and US contexts through
the 1990s [2-8], culminating in a recent study of colon
cancer treatment accessibility and survival in Toronto,
Ontario, and San Francisco, California that followed its
cohorts until 2006 [9]. In the United States, people with
colon cancer who lived in low-income areas experienced
less thorough lymph node evaluations and were less
likely to receive indicated chemotherapies or to survive.
More inclusive health insurance in Canada was advanced
as the most plausible explanation.
All of these studies were ecological with respect to the
measurement of socioeconomic status (SES). They typic-
ally used census tract data to define low-income neigh-
borhoods where cancer patients lived, however, their
lowest income areas only ranged from 10% to 20% poor.
So they had limited power to study cancer care among
“the truly disadvantaged” [10] who live, for example, in
America’s poorest neighborhoods where 30% to 40%
or more of the households have incomes below the
poverty line [10-12]. Recent synthetic and exploratory
analyses have suggested the potential great policy
importance of such study [13,14] and studies of colon
cancer care may be particularly instructive in such con-
texts for several reasons.
First, colon cancer is the second most frequent cause
of cancer death in America and its prognosis can be ex-
cellent with early diagnosis and treatment [15]. Second,
generally modest inverse associations between income
and colon cancer survival have been consistently
observed in the US [1,9,16-19]. Third, as colon cancer
screens have begun to be implemented and as effective
chemotherapies proliferated during the 1990s for stage
III colon cancer and more recently for stage II disease
[20-22], evidence has mounted that the best care, from
initial screening, through diagnostic investigations to
follow-up care, is more accessible to people with higher
SES [9,22-29]. Fourth, various underinsured statuses
have also been associated with less than optimum colon
cancer care in America [22,23,30-36]. Similar to inter-
national studies, these US studies have for the most
part had insufficient power to study the quality of
colon cancer care among those at greatest risk of not
receiving it; the poor and the uninsured. Their samples
of such people have tended to be quite small or non-
existent. One naturally wonders if even larger colon
cancer survival disadvantages would be observed, for
example, among more extremely poor people living in
America’s most impoverished places where health risks,including the risk of not having health insurance, are
most prevalent.
Combined effects of being underinsured and living in
extremely poor communities
Our previous within-US and Canada-US comparative
studies of cancer care have allowed us to develop the
theory that SES-cancer care relationships are probably
mediated by health insurance [9,13,37]. We think that it
is also probable that within the multi-payer US health
care system the effects of various payers (self, Medicaid,
Medicare and/or various private insurance companies)
interact with other socioeconomic resources, personal
and community, in complex ways that have not yet been
studied. In fact, thus far this field has primarily advanced
knowledge about main effects, that is, hypotheses
about the independent effects of SES or various payers
have been tested alone. More complex hypotheses
about mediation and moderation effects have not been
formally tested.
Our SES-payer-cancer care mediation theory borrows
constructs from sociology, medicine and public health,
and aims principally to model care gaps in America’s
most vulnerable communities. Its foundation is William
Julius Wilson’s germinal work in 1960s Chicago’s
high poverty neighborhoods (30% or more poor) and
Paul Jargowsky and Mary Jo Bane’s construct validation
of hundreds of extremely poor neighborhoods (40%
or more poor) across America between 1970 and 1990
[10-12]. Together they described places of prevalent
demographic vulnerability that are particularly distressed
for their lack of social and economic capital. In addition
to the poor, all of the following groups of people tend
to be more concentrated there: ethnic and racial minor-
ity group members, recent immigrants, young adults
without a high school diploma, single mothers, the un-
employed and those who have withdrawn from the labor
market, part-time service workers versus full time skilled
workers or professionals, renters versus home owners,
welfare recipients and the homeless. Medicaid and Medi-
care, the government’s, respective, mean-tested and en-
titlement, health care programs were specifically designed
to mediate the effects of such concentrated impoverish-
ment. But SES and various payers, including private ones,
probably interact in other important ways across Ameri-
ca’s economic divide.
A recent survey practically demonstrated how SES and
health insurance status could interact in the lives of real
people with colon cancer. It surveyed nearly 300 people
with stage III colon cancer, most of whom were insured
and found that more than a third of them (38%) suffered
one or more significant financial hardships as a result
of their treatment [38,39]. These included selling or refi-
nancing their home, borrowing money from friends or
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and prematurely withdrawing money from retirement
accounts. Moreover, more than one of every ten of them
reported coverage denials by their insurers and conse-
quently one of every ten to fifteen of them was not able
to adhere to their prescribed treatment regime. And per-
haps not surprisingly, low-income households were
much more likely to be so impacted. So it seems that
the ultimate effectiveness of various health insurance
programs may be significantly impacted or moderated
by other available resources. And those most likely to
be disadvantaged are the poor. It is they who will prob-
ably be least likely to pick up the indirect costs (time
lost from work for numerous treatment visits, recuper-
ation and perhaps travel) and direct, but uncovered costs
(co-insurance and co-payments) of contemporary cancer
care in America.
The objective of this study was to evaluate the mediat-
ing and moderating effects of SES and health insurance
payer status on cancer care in extremely poor communi-
ties in the US. We hypothesized that the inverse
poverty-colon cancer survival relationship would be
mediated by payers (any payer would be better than
being uninsured). We also hypothesized that the direct
payer-colon cancer survival relationship would be mod-
erated by poverty (all payers would be less effective in
high poverty neighborhoods). Because gender is well
known to be strongly associated with being poor and
uninsured in the US [40,41] and our preliminary ana-
lyses suggested that survival disadvantages associated
with poverty were greater for women than for men with
colon cancer, we based our analyses upon the explora-
tory hypotheses that mediation and moderation effects
would both be stronger among women. We then
explored similar mediation and moderation hypotheses
across the colon cancer care continuum: thoroughness
of diagnostic investigation, stage of disease at diagnosis,
receipt of and wait times for surgery and adjuvant
chemotherapy, and receipt of palliative care.
Methods
The sampling frame was the California cancer registry
which monitors the most populous US state. It ascer-
tains nearly all colon cancer cases with a nearly perfect
rate of microscopic confirmation [42,43]. Registry data
was obtained for 6,300 colon cancer cases diagnosed be-
tween 1996 and 2000 (International Classification of
Diseases, Ninth Revision code 153 [44]) and followed
until 2011. Cases were randomly selected from 3 place
and 3 poverty strata: megalopolises with between 3
and 12 million residents (greater San Diego, the San
Francisco Bay area and greater Los Angeles), smaller
metropolitan areas with populations between 400,000
and 900,000 (Salinas, Modesto, Stockton, Bakersfieldand Fresno), and small rural places with populations of
less than 10,000 and population densities less than 400
per km2 [45-47]. Overall, we sampled 15.4% of the colon
cancer cases that were diagnosed in these places be-
tween 1996 and 2000. This study was powered to detect
a difference of 5% in survival rates for women and men
across 3 places and 3 poverty groups with 80% power
at a 2-tailed significance level of 5% [48,49]. A 15% over-
sample was drawn to account for unstaged cases and
other missing data.
Variables
Poverty and payers
We first linked colon cancer patients to the US (2000)
census by their residential census tract at diagnosis [45].
Next, to model our poverty measure after those that
have been most validated, we defined the following
neighborhoods: high poverty (30% or more poor), mid-
dle poverty (5-29%) and low poverty (less than 5% poor)
[10-14,50-52]. The prevalence of poverty in the typical
high poverty neighborhood was 36%, just about mid-
point between Wilson’s (30%) and Jargowsky and Bane’s
(40%) criterion definitions of high poverty. And the typ-
ically, quite low, annual household income in such high
poverty neighborhoods of $23,150 was much lower than
that of typical households in middle ($42,475) or low
poverty ($75,050) neighborhoods. Health insurance sta-
tus, defined as the primary source of payment to the
hospital or primary payer, was determined from medical
records during the initial course of cancer directed treat-
ment. It was categorized as follows: uninsured (self-pay
or no source of payment), Medicaid, Medicare (with or
without any supplementation or any other non-means-
test-based governmental payer: Veterans Affairs, TRI-
CARE, the health care program for military service
members, retirees and their families or the Indian Public
Health Service) or private insurer (any managed care
corporation or fee-for-service provider).
Colon cancer care
Variables were routinely extracted from hospital and
physicians’ office patient charts and clinic reports and
coded by the California cancer registry [53-55]. These
were stage of disease at diagnosis (according to the
American Joint Committee on Cancer guidelines) [54],
receipt of initial surgery, number of regional lymph
nodes harvested for evaluation, receipt of adjuvant
chemotherapy, wait times from diagnosis to surgery and
chemotherapy, and survival time from diagnosis to death
or last follow-up to 10 years. Defining characteristics of
cancer stages were stage I (invasion into bowel wall
muscle), stage II (invasion through bowel wall muscle),
stage III (metastasized to at least 1 regional lymph node)
and stage IV (distally metastasized). Stage 0 or in situ
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gested a range of harvested lymph nodes, from 10 to 16
or more, as well as a range of surgical and post-surgical
wait times for chemotherapy (1 month, 2 months or
3 months) that may be of clinical importance [56-62].
They were all examined.
Statistical analyses
We used logistic or binomial regression models to test
hypotheses about the mediating and interaction effects
of poverty and payer in predicting binary (survived or
not) all-cause colon cancer survival [63-65]. Odds ratios
(ORs) and 95% confidence intervals (CIs) were esti-
mated. Modest amounts of missing data would not
enter regression models as discrete variables (yes or
no) so they probably could not have confounded
these analyses. We tested 2-way (gender-by-poverty
and gender-by-payer) and 3-way interactions (gender-
by-poverty-by-payer) that involved gender. When any
of these interactions were significant we assumed the
pattern of findings to be different for women and men
and reported them separately. Remarkably similar
poverty-payer-survival patterns were observed across 2- to
10-year survival analyses. The 6-year analyses were
reported as they were the best fit for women and men
(Hosmer-Lemeshow test [63,66]).
Logistic regressions were used as statistical tests of
complex models involving mediating and moderating
effects and their ORs estimate the relative predictive
weights of such interacting effects along with main
effects. However, under the circumstances of this study,
where both “exposures” (e.g., a third of the sample was
selected from high poverty neighborhoods) and key out-
comes (e.g., 6-year survival was 46% for the entire sam-
ple) are common, ORs probably overestimate rate ratios
(RRs) [67]. So we provided accompanying practical
assessments more germane perhaps to clinical and pol-
icy significance. All rates were directly adjusted for rele-
vant covariates (age, stage, poverty and/or payers) using
this study’s sample as the standard. Then we used stan-
dardized RRs for all between-group comparisons with
95% CIs derived from the Mantel-Haenszel χ2 test
[68,69]. The statistical interaction is displayed at the bot-
tom of Table 3, Corresponding practical significance in-
dices (RRs) can be found in the Additional file. Finally,
this study was reviewed and cleared by the University of
Windsor’s research ethics board.
Results
Sample description
The two key study variables of neighborhood poverty
and primary payer are cross-tabulated in Table 1. People
with colon cancer living in high poverty California
neighborhoods were nearly twice as likely to beuninsured, five to nearly seven times as likely to be pri-
marily insured by Medicaid, but only two-thirds to half
as likely to be so covered by a private insurer as were
their counterparts in low poverty neighborhoods. In a
practical sense, all of the disadvantages seemed to be
substantively greater for women. More detailed descrip-
tive profiles of the California colon cancer patients in
our sample are displayed in Table 2. A few characteris-
tics stand out. This sample seems representative of
California’s diverse places, including high poverty neigh-
borhoods where 30% or more of the households have
aggregate annual incomes below the poverty live. As
planned, a third of our sample lived there, while another
third resided in so-called middle poverty neighborhoods
that actually are still quite poor, with 5% to 29% of the
household living below the poverty line. Demographic-
ally, our sample of generally older people with colon
cancer seems consistent with expectations, nearly half of
them covered by Medicare (44%). The relatively low rep-
resentation of the uninsured (8%) may seem surprising.
The vast majority of colon cancer care took place in
hospitals where social work staff would work to connect
patients who may have been uninsured at the time
of their admission to any additional resources such as
Medicaid or Medicare for which they qualified by virtue
of being poor, older or disabled.
Mediation (poverty-payer-survival) and moderation
(poverty-by-payer) survival hypotheses
Single predictor and full logistic regression models for 6-
year colon cancer survival among women and men are
displayed in Table 3. Substantial support for both the
mediation and moderation hypotheses was observed for
women, but not for men. The top, left column, shows
significant main effects of poverty and all payers (versus
being uninsured) among women when these factors
entered regression models alone. Moving down the col-
umn to the full model for women, consistent with medi-
ation, the table shows that in the presence of payer the
effect of poverty disappeared and effects of all of the
payers were maintained or perhaps even strengthened.
The 6-year survival rates among women whose primary
payers were Medicaid (RR = 1.83), Medicare (RR = 1.92)
or a private insurer (RR = 1.83) were all nearly twice that
of uninsured women only 26% of whom so survived.
The hypothesis that the payer-colon cancer survival
relationship would be moderated by poverty was also
supported for women, but not for men. The statistical
interaction is displayed at the bottom of Table 3, while
the practical effect moderation is depicted at the bottom
of Additional file 1. Among women, all of the payers
seemed less effective in high poverty neighborhoods
than in low poverty neighborhoods and Medicaid did
not seem any more effective than having no insurance.
Table 1 Primary payers among women and men with colon cancer diagnosed between 1996 and 2000 in low, middle
and high poverty neighborhoods: prevalence estimates and prevalence ratios
Neighborhood poverty Women Men
By primary payer No.a Prevalence PR (95% CI) No.a Prevalence PR (95% CI)
Low Poverty
Uninsured 60 .056 1.00 67 .066 1.00
Medicaid 12 .017 1.00 16 .014 1.00
Medicare 437 .402 1.00 358 .381 1.00
Private 552 .535 1.00 598 .542 1.00
Middle Poverty
Uninsured 74 .069 1.23 (0.91, 1.67) 77 .075 1.14 (0.83, 1.56)
Medicaid 48 .050 2.94 (1.79, 4.83) 26 .026 1.86 (1.04, 3.33)
Medicare 549 .453 1.13 (1.02, 1.25) 408 .436 1.14 (1.03, 1.26)
Private 438 .430 0.80 (0.73, 0.87) 480 .467 0.86 (0.79, 0.94)
High Poverty
Uninsured 105 .098 1.75 (1.30, 2.35) 107 .103 1.56 (1.17, 2.07)
Medicaid 110 .110 6.47 (4.29, 9.75) 72 .068 4.86 (2.89, 7.93)
Medicare 587 .501 1.25 (1.14, 1.37) 451 .486 1.28 (1.16, 1.42)
Private 319 .295 0.55 (0.50, 0.61) 349 .347 0.64 (0.58, 0.71)
Notes. PR = standardized prevalence ratio, CI = confidence interval. Confidence intervals were derived from the Mantel-Haenszel χ2 test. All adjustments were
internal and direct, using this study’s population of colon cancer cases as the standard. A prevalence ratio of 1.00 was the between-place baseline. Middle and
high poverty neighborhood payer prevalence estimates were compared to payer prevalence estimates in low poverty places.
a Number of incident colon cancer cases.
b Prevalence estimates were age-adjusted across these categories: 25–59, 60–69, 70–79 and 80 or older.
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and economic capital is available in more affluent, low
poverty neighborhoods, the 6-year survival rates there
among women whose primary payers were Medicaid
(RR = 2.90), Medicare (RR = 2.91) or a private insurer
(RR = 2.60) were all nearly three times that of uninsured
women who lived there. As for men, only significant
main effects of poverty and payer were observed.
Effects of being uninsured or underinsured and living in
extremely poor neighborhoods on colon cancer
investigations, diagnoses and treatments
Investigation and stage at diagnosis
Generally modest effects of poverty and payer that did
not differ significantly by gender demonstrated the
lymph node investigation criterion of 15 or more to be
most predictive in this sample. A significant poverty by
payer interaction was also found (left column of Table 4).
In low poverty areas, colon cancer patients whose pri-
mary payer was Medicare were nearly twice as likely
(RR = 1.91) to have had 15 or more regional lymph
nodes harvested during surgery for diagnostic evaluation
than were the uninsured. Trends in the same direction
that were not statistically significant, however, were
observed for those primarily covered by Medicaid or pri-
vate insurers. The combined any payer versus uninsured
effect among those who lived in such more affluent
neighborhoods approached significance (RR = 1.64; 90%CI = 1.06, 2.53, data not shown). No such effects of any
payers were observed in high or middle poverty neigh-
borhoods. There were only, relatively small, main effects
of poverty and payer on early diagnosis of stage I or
stage II disease.
Surgery and adjuvant chemotherapy
The effects of poverty and payer on the receipt of sur-
gery for colon cancer patients with non-metastasized
disease are displayed in Table 5. There were no apparent
interaction effects. Full statistical models suggested
disadvantaging effects of living in high poverty neighbor-
hoods among women and middle poverty neighborhoods
among men. They also strongly suggested the protective
effects of Medicaid coverage for women (OR = 10.14)
and private health insurance coverage for men (OR =
9.98). In a practical sense, any health insurance coverage
(private, Medicare or Medicaid) increased surgical rates
by 13% to 16% (RRs of 1.13 to 1.16). While practically
all insured patients received such indicated care, only
86% of uninsured patients did. There were no significant
main or interaction effects of poverty or primary payer
on any surgical wait times.
The effects of poverty and payer on the receipt of
adjuvant chemotherapy for colon cancer patients with
stage II or stage III disease are displayed in Table 6.
Three findings stand out. First, patients who lived in
high poverty neighborhoods were 18% less likely to have
Table 2 Stratification, demographic, payer, investigation, staging and care characteristics of colon cancer patients
diagnosed between 1996 and 2000 and followed until 2011
Sample % Sample %
Stratification Characteristics
Places Poverty prevalence (%) in neighborhood
Large urban 2,100 33.3 < 5 2,100 33.3
Smaller urban 2,100 33.3 5–29 2,100 33.3
Rural 2,100 33.3 ≥ 30 2,100 33.3
Demographic Characteristics
Age at diagnosis, y Gender
25–59 1,347 21.4 Female 3,291 52.2
60–69 1,372 21.8 Male 3,009 47.8
70–79 1,919 30.5
≥ 80 1,662 26.3
Race/ethnicity Primary Payers
Non-Hispanic white 4,199 66.7 Medicare 2,790 44.3
Non-Hispanic black 688 10.9 Private insurers 2,736 43.4
Hispanic 810 12.9 Medicaid 284 4.5
API or American Indian 603 9.6 Uninsured 490 7.8
Investigation and Staging Characteristics
Number of regional lymph nodes examined Stage at diagnosisa
< 6 2,199 37.5 I 1,300 22.5
6–10 1,513 25.8 II 1,882 32.6
11–14 874 14.9 III 1,392 24.1
≥ 15 1,278 21.8 IV 1,202 20.8
Missing data 436 6.9 Missing data 524 8.3
Cancer Care Characteristics
Received surgeryb 5,506 88.7 Received chemotherapy 1,751 28.3
Missing data 90 1.4 Missing data 115 1.8
Wait time from diagnosis to surgery, d Wait time after surgery for chemotherapy, d
< 14 3,960 71.7 < 14 194 12.0
14–29 1,031 18.7 14–29 415 25.7
30–59 408 7.4 30–59 733 45.3
≥ 60 120 2.2 60–89 159 9.8
Missing data 781 12.4 ≥ 90 116 7.2
Missing data 134 7.6
Note. API = Asian-Pacific Islander.
a American Joint Commission on Cancer staging [54].
b 5,227 were resections and 279 were local excisions.
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counterparts in low poverty neighborhoods (OR = 0.65,
RR = 0.82). Second, the statistical models suggested that
the poverty-chemotherapy wait time relationship might
be mediated by payer as there seemed some attenuation
of that poverty-therapy relationship in the presence of
payer (unadjusted OR = 1.55; 95% CI = 1.04, 2.30 and
adjusted OR = 1.33; 95% CI = 0.88, 2.02). In practical
terms though, poverty and payer seemed independently
important. The very poor were much more likely thanthe affluent to wait for 2 months or more after surgery
to receive chemotherapy (RR = 1.38) and those with
Medicare or private health insurance were half as likely
as the uninsured or those with Medicaid to wait that
long (RR = 0.52).
We developed a nominal measure of optimum treat-
ment of stage III colon cancer from four study variables:
received colon-cancer directed surgery within 30 days of
diagnosis and received adjuvant chemotherapy within
45 days of surgery. Admittedly, it is probably only one of
Table 3 Logistic regression results for main effects and interactions of neighborhood poverty and primary payer by
gender on 6-year colon cancer survival
Women Men
Predictor variables No.a OR (95% CI) No.a OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 1,061 1.00 1,039 1.00
5-29% poor 1,109 0.76 (0.64, 0.91) 991 0.68 (0.57, 0.82)
≥ 30% poor 1,121 0.62 (0.52, 0.74) 979 0.57 (0.48, 0.69)
Primary payer
Uninsured 239 1.00 251 1.00
Medicaid 170 2.01 (1.31, 3.08) 114 1.24 (0.78, 1.99)
Medicare 1,573 2.48 (1.79, 3.43) 1,217 1.82 (1.34, 2.48)
Private 1,309 2.78 (2.02, 3.83) 1,427 2.36 (1.76, 3.16)
Full models
Neighborhood poverty
< 5% poor 1,061 1.00 1,039 1.00
5-29% poor 1,109 1.07 (0.78, 1.48) 991 0.70 (0.58, 0.84)
≥ 30% poor 1,121 1.25 (0.71, 2.18) 979 0.62 (0.52, 0.75)
Primary payer
Uninsured 239 1.00 251 1.00
Medicaid 170 2.40 (1.55, 3.73) 114 1.33 (0.83, 2.12)
Medicare 1,573 3.93 (2.33, 6.64) 1,217 1.79 (1.31, 2.44)
Private 1,309 3.66 (2.36, 5.67) 1,427 2.19 (1.63, 2.93)
Poverty by payer 3,291 0.87 (0.78, 0.98) Null interaction removed
Poverty by payer interaction among women
> 30% poor 5-29% poor < 5% poor
No.a OR (95% CI) No.a OR (95% CI) No.a OR (95% CI)
Primary payer
Uninsured 105 1.00 74 1.00 60 1.00
Medicaid 110 1.60 (0.90, 2.84) 48 1.83 (0.82, 4.07) 12 5.94 (1.50, 23.54)
Medicare 587 1.68 (1.03, 2.74) 549 2.65 (1.48, 4.75) 437 4.69 (2.30, 9.57)
Private 319 1.92 (1.18, 3.13) 438 2.61 (1.47, 4.64) 552 5.03 (2.51, 10.08)
Notes. OR = odds ratio, CI = confidence interval. All effects were age-adjusted across these categories: 25–59, 60–69, 70–79 and 80 or older. After age, poverty
and payer were accounted for, place (large urban, smaller urban, rural) did not enter the full models for women or men.
a Number of incident colon cancer cases.
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ure of clinical validity. A statistical main effect of poverty
was observed for women and a poverty-by-payer inter-
action effect was observed for men (Table 7). In low
poverty neighborhoods about 7 of every 10 patients with
stage III colon cancer received such optimum care and
this outcome did not differ significantly between women
and men. In high poverty neighborhoods, however, 20%
fewer women received such optimum care (RR = 0.80).
For men, there was no main effect of poverty, but there
was an effect of payer in high poverty neighborhoods.
Only 4 of every 10 such men in very poor neighbor-
hoods who were either uninsured or insured by Medic-
aid received optimum care. Similarly poor men with
Medicare or private health insurance were more than60% more likely to have received optimum care (RR =
1.62). We also compared very poor uninsured men with
very poor men who were insured by any payer, public or
private. The vast majority of such uninsured men did
not receive optimum care (29%). However, very poor
men with any type of health insurance were more than
twice as likely to have received optimum care (RR = 2.30;
95% CI = 1.10, 1.43, data not shown). Rates for patient
refusal of chemotherapy were similar (3% overall) be-
tween poverty and payer groups.
Experimental and palliative chemotherapies
Chemotherapy for stage II colon cancer, experimental at
the time of this study was not associated with gender or
payer. But it was less likely to have been received by
Table 4 Logistic regression results for main effects and interactions of neighborhood poverty and primary payer on
high quality investigation and early stage at diagnosis
15 or more regional lymph nodes examined Stage I or stage II at the time of diagnosis
Predictor variables No.a OR (95% CI) No.a OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 1,727 1.00 1,959 1.00
5-29% poor 1,646 0.92 (0.79, 1.07) 1,923 0.81 (0.72, 0.92)
≥ 30% poor 1,583 0.95 (0.81, 1.11) 1,894 0.89* (0.79, 1.01)
Primary payer
Uninsured 241 1.00 310 1.00
Medicaid 229 2.01 (0.74, 1.65) 261 1.06 (0.77, 1.48)
Medicare 2,221 1.11 (0.81, 1.53) 2,601 1.33 (1.04, 1.71)
Private 2,265 0.97 (0.72, 1.30) 2,604 1.30 (1.03, 1.65)
Full models
Neighborhood poverty
< 5% poor 1,727 1.00 1,959 1.00
5-29% poor 1,646 1.34* (0.99, 1.80) 1,923 0.82 (0.72, 0.93)
≥ 30% poor 1,583 1.97 (1.17, 3.32) 1,894 0.91 (0.80, 1.04)
Primary payer
Uninsured 241 1.00 310 1.00
Medicaid 229 1.30 (0.86, 1.98) 261 1.07 (0.77, 1.49)
Medicare 2,221 2.03 (1.22, 3.41) 2,601 1.33 (1.03, 1.70)
Private 2,265 1.49* (0.97, 2.29) 2,604 1.28 (1.01, 1.63)
Poverty by payer 4,956 0.85 (0.76, 0.94) Null interaction removed
Poverty by payer interaction on high quality investigation
> 30% poor 5-29% poor < 5% poor
No.a OR (95% CI) No.a OR (95% CI) No.a OR (95% CI)
Primary payer
Uninsured 114 1.00 72 1.00 55 1.00
Medicaid 144 1.11 (0.65, 1.88) 63 0.70 (0.32, 1.53) 22 1.91 (0.63, 5.79)
Medicare 794 0.93 (0.58, 1.48) 753 0.92 (0.52, 1.63) 674 2.01 (1.02, 3.99)
Private 531 1.00 (0.64, 1.57) 758 0.85 (0.50, 1.45) 976 1.32 (0.68, 2.55)
Notes. OR = odds ratio, CI = confidence interval. All effects were age-adjusted across these categories: 25–59, 60–69, 70–79, and 80 or older.
a Number of incident colon cancer cases.
* p < .10.
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http://www.biomedcentral.com/1471-2458/12/897patients in mid- to high poverty (17%) than in low pov-
erty (25%) neighborhoods (RR = 0.68; 95% CI = 0.57,
0.82). We also found a poverty-by-payer interaction such
that in middle poverty neighborhoods the privately
insured may have been slightly more likely to have
received chemotherapy than were others, respectively,
24% and 18% (RR = 1.29; 90% CI = 1.00, 1.66). Finally, we
considered receipt of palliative chemotherapy by those
with stage IV colon cancer. Straightforward independent
main disadvantaging effects of mid- to high poverty
(44% versus 56%, RR = 0.80; 95% CI = 0.71, 0.90) and
being uninsured or covered by Medicaid (38% versus
51%, RR = 0.75; 95% CI = 0.62, 0.91) that did not differ
between women and men were observed.Discussion
To the best of our knowledge, this is the first report of
the combined effects of poverty and health insurance on
colon cancer care in high poverty US neighborhoods.
We found strong support for our hypothesis that health
insurance mediates the poverty-colon cancer survival
relationship for women. The apparent effect of poverty
disappeared in the presence of payer and the effects of
all forms of health insurance seemed strengthened. All
were associated with substantial survival advantages
compared to the uninsured: Medicaid (RR = 1.83), Medi-
care (RR = 1.92) and private (RR = 1.83). We also found
support for our poverty-by-health insurance interaction
hypothesis for women. The survival effects of all forms
Table 5 Logistic regression results for main effects of neighborhood poverty and primary payer by gender on receipt
of colon cancer surgery among patients with non-metastasized disease
Women Men
Predictor variables No.a OR (95% CI) No.a OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 774 1.00 713 1.00
5-29% poor 762 0.50* (0.24, 1.06) 675 0.32 (0.11, 0.90)
≥ 30% poor 761 0.38 (0.19, 0.78) 637 0.35* (0.12, 1.01)
Primary payer
Uninsured 94 1.00 109 1.00
Medicaid 113 9.66 (1.12, 83.68) 74 2.49 (0.26, 23.47)
Medicare 1,135 5.12 (1.85, 14.20) 844 3.80 (1.06, 13.58)
Private 955 3.39 (1.30, 8.88) 998 10.09 (2.62, 38.85)
Full models
Neighborhood poverty
< 5% poor 774 1.00 7.13 1.00
5-29% poor 762 0.49* (0.23, 1.03) 675 0.32 (0.11, 0.91)
≥ 30% poor 761 0.37 (0.18, 0.77) 637 0.41 (0.14, 1.19)
Primary payer
Uninsured 94 1.00 109 1.00
Medicaid 113 10.14 (1.17, 87.92) 74 2.82 (0.30, 26.85)
Medicare 1,135 4.43 (1.58, 12.47) 844 3.93 (1.08, 14.27)
Private 955 2.65* (0.99, 7.08) 998 9.98 (2.53, 39.33)
Notes. OR = odds ratio, CI = confidence interval. All effects were age- and stage-adjusted across these categories: 25–59, 60–69, 70–79 and 80 or older; and
stage I, stage II and stage III.
* p < .10.
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borhoods than they were in poor to very poor neighbor-
hoods: Medicaid (RR = 2.90), Medicare (RR = 2.91) and
private (RR = 2.60). It seems that the effectiveness of all
health insurance programs is significantly impacted by
the availability of other key resources. In more well to
do neighborhoods where social and economic capital
abounds most people with colon cancer seem quite able
to absorb the indirect and additional uncovered, direct
costs of cancer care. High poverty neighborhoods on the
other hand, with their relative lack of such capital
reserves, seem to remain as described more than a gen-
eration ago by William Julius Wilson, places of “true dis-
advantage” [10], places of multiplicative disadvantage,
especially for the women who live there. Not only are
they much more likely to be uninsured (2 times as likely
as less poor women) or underinsured (more than 6 times
as likely to be covered by Medicaid), but when insured,
all such insurance programs, public and private, seem to
be much less effective there than they are in less poor
places. There is even some evidence to suggest that
being covered by Medicaid may be no more beneficial
than being uninsured among many women who live in
such extremely poor places.For men, poverty and health insurance still seem to
matter very much, but in more straightforward ways, as
independent main effects. Across colon cancer care pro-
cesses, poverty and public payers, particularly Medicare,
seemed more instrumental for women while private
payers slightly more so for men. Such stands to reason
given the facts that other than government health care
insurance programs are predominantly purchased
through employers in the US and over the life times of
these generally now older people with colon cancer such
opportunities have been much more available to men
than to women.
Potential limitations
Internal validity
Our use of ecological poverty measures might suggest
alternative explanations for our results though we
intended them to be contextual neighborhood measures,
rather than compositional personal measures. Still, one
might wonder if the racial/ethnic composition of high
poverty neighborhoods, rather than their concentration
of poor households, accounted for the colon cancer
survival differences we observed. First, recent US studies
of colon cancer diagnosis, treatment and survival have
Table 6 Logistic regression results for main effects of neighborhood poverty and primary payer on chemotherapy
receipt and post-surgical wait for chemotherapy of 60 days or more among patients with stage II or stage III colon
cancer
Single predictor models Full models
Predictor variables No.a OR (95% CI) No.a OR (95% CI)
Received chemotherapy after surgery
Neighborhood poverty
< 5% poor 1,103 1.00 1,103 1.00
5-29% poor 1,066 0.80 (0.65, 0.98) 1,066 0.80 (0.65, 0.98)
≥ 30% poor 1,045 0.63 (0.52, 0.78) 1,045 0.65 (0.52, 0.80)
Primary payer
Uninsured 164 1.00 164 1.00
Medicaid 147 0.49 (0.30, 0.81) 147 0.51 (0.31, 0.85)
Medicare 1,436 0.75 (0.51, 1.11) 1,436 0.71* (0.48, 1.04)
Private 1,467 0.85 (0.60, 1.22) 1,467 0.75 (0.52, 1.09)
Waited 60 days or more for adjuvant chemotherapy
Neighborhood poverty
< 5% poor 421 1.00 421 1.00
5-29% poor 369 1.48 (1.01, 2.18) 369 1.45* (0.98, 2.14)
> 30% poor 326 1.55 (1.04, 2.30) 326 1.33 (0.88, 2.02)
Primary payer
Uninsured 90 1.00 90 1.00
Medicaid 58 0.87 (0.40, 1.86) 58 0.85 (0.39, 1.83)
Medicare 364 0.42 (0.24, 0.76) 364 0.43 (0.24, 0.77)
Private 604 0.41 (0.24, 0.69) 604 0.43 (0.25, 0.73)
Notes. OR = odds ratio, CI = confidence interval. All effects were age- and stage-adjusted across these categories: 25–59, 60–69, 70–79 and 80 or older; and
stage II or stage III.
* p < .10.
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explained most racial-group differences [26,70-74]. Sec-
ond, although we did not account for this factor in the
present analysis as it was outside its scope, we are con-
comitantly performing related analyses that will soon be
reported. We have found, for example, that health insur-
ance also mediates ethnicity-breast cancer care relation-
ships, accounting for many of the disadvantages
observed among Hispanic women. In short, while not
refuting previous inferences about the importance of
race, ethnicity and culture in cancer care, our analyses
suggest that having adequate health insurance is prob-
ably much more important.
For now, we do not think that race/ethnicity con-
founded this analysis for the following reasons. Two-
thirds of our sample was comprised of non-Hispanic
white people. Even within our subsample of high poverty
neighborhood residents, nearly half of them were non-
Hispanic white people. Most importantly, we were able
to systematically replicate both our mediation and mod-
eration hypothesis tests for non-Hispanic white women
and women of color (Hispanic, non-Hispanic black,
Asian-Pacific Islanders and American Indian people) aswell as systematically replicate similar main effects of
poverty and health insurance for non-Hispanic men and
for men of color.
There has been a largely unmet need for research on
the construct validity of ecological socioeconomic mea-
sures that are so often used in public health research.
Wilson, Jargowsky and Bane added much relevant know-
ledge on high poverty neighborhood measures [10-12],
and our research group has done some work to advance
understandings of poor neighborhoods, analogous to this
study’s middle poverty neighborhoods [2,3]. They seem
prevalently represented by not only the poor, but the
near poor and working poor as well as lower-middle and
middle class people. This study added further to our
knowledge about vulnerable neighborhoods. For the first
time that we are aware, steep monotonic gradients were
observed for various types of health insurance across
low poverty (e.g., baseline Medicaid coverage of women),
middle poverty (prevalence 3-fold greater) and high pov-
erty neighborhoods (prevalence more than 6-fold
greater, Table 1 [75,76]). This new knowledge concerning
the construct validity of ecological poverty measures
may advance our understanding about the context in
Table 7 logistic regression results for main effects and interactions of neighborhood poverty and primary payer by
gender on receipt of optimum treatmenta among colon cancer patients with stage III disease
Women Men
Predictor variables No.b OR (95% CI) No.b OR (95% CI)
Single predictor models
Neighborhood poverty
< 5% poor 133 1.00 133 1.00
5-29% poor 131 0.53 (0.32, 0.88) 115 0.98 (0.58, 1.66)
≥ 30% poor 109 0.55 (0.32, 0.95) 103 0.88 (0.51, 1.50)
Primary payer
Uninsured 29 1.00 27 1.00
Medicaid 24 0.84 (0.26, 2.72) 15 0.67 (0.19, 2.42)
Medicare 131 0.52 (0.21, 1.30) 119 1.47 (0.59, 3.66)
Private 189 0.86 (0.37, 2.00) 190 1.06 (0.46, 2.44)
Full models
Neighborhood poverty
< 5% poor 133 1.00 133 1.00
5-29% poor 131 0.53 (0.32, 0.89) 115 0.28 (0.10, 0.77)
≥ 30% poor 109 0.55 (0.31, 0.98) 103 0.08 (0.01, 0.47)
Primary payer
Uninsured 29 1.00 27 1.00
Medicaid 24 0.82 (0.25, 2.68) 15 0.41 (0.10, 1.70)
Medicare 131 0.47 (0.19, 1.21) 119 0.22* (0.04, 1.20)
Private 189 0.72 (0.30, 1.72) 190 0.27* (0.07, 1.06)
Poverty by payer Null Interaction removed 351 1.75 (1.19, 2.57)
Poverty by payer interaction among men
> 30% poor < 30% poor
No.b OR (95% CI) No.b OR (95% CI)
Primary payer
Uninsured 10 1.00 17 1.00
Medicaid 9 3.03 (0.43, 21.33) 6 0.22 (0.03, 1.69)
Medicare 37 13.33 (2.42, 73.50) 82 0.40 (0.10, 1.60)
Private 47 3.69* (0.81, 16.84) 143 0.41 (0.11, 1.51)
Notes. OR = odds ratio, CI = confidence interval. All effects were age-adjusted across these categories: 25–59, 60–69, 70–79 and 80 or older.
a Optimum treatment: received colon cancer-directed surgery within 30 days of diagnosis and received adjuvant chemotherapy within 45 days of surgery.
b Number of incident colon cancer cases.
* p < .10.
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are probably not prone to ecological fallacy. They may,
in fact, help researchers to better understand their con-
textual measures and so avoid individualistic fallacies of
inference [77,78]. Finally, the preferential predictive val-
idity of our census tract-based poverty measure was con-
sistent with that observed by others [50,51]. After such
poverty measures entered this study’s analytic models,
no education or occupation-based measures did.
Another possible limitation of our study was incom-
plete information on outpatient treatments [79,80]. Such
data are more difficult for cancer registries to collect
than inpatient data. However, the California cancer
registry has been shown to be nearly complete forchemotherapy data (85%) in one place that we sampled,
San Francisco [81]. In addition, analyses of hospital-
based surgery, lymph node evaluation, stage and survival
were unlikely to have been affected [82], and missing
chemotherapy data were not prevalent in our sample.
We focused on all-cause or overall survival, rather
than cancer-specific survival. Cancer was the underlying
cause of death among the vast majority of patients in
our sample (72%) who died during the study period,
accounting for nearly 8 of every 10 deaths (78%), for ex-
ample, among perhaps the most policy-interesting group
for its observed socioeconomic gradients, those with
stage III colon cancer. Although vital status and length
of overall survival are highly accurate in cancer
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[83-85]. Although death certificate error was a likely
limitation, we did systematically replicate our central all-
cause survival hypothesis tests with cancer-specific ones.
If anything, our overall survival effects were probably
slight underestimates of cancer-specific ones [84].
Finally, the underlying cause of many deaths not coded
as cancer mortality can be directly associated with lack
of treatment or with cancer treatment complications
[86]. For all of these reasons, we think overall survival a
more policy-telling indicator of practical clinical and
human significance.
External validity
This study’s sample of people with colon cancer may not
be generalizable to all such people across the US. Pur-
posively diverse and potentially policy-important places
in California were oversampled: high poverty neighbor-
hoods in very large urban to rural places. Admittedly,
our findings are most generalizable to such places. Previ-
ous research has suggested that such high poverty places
probably have some important commonalities across
America [10-12]. It should also be noted that after
accounting for demographic, socioeconomic and clinical
factors, place (large urban, smaller urban or rural) did
not seem to matter in this study’s analytic models. This
study’s inferences, therefore, can probably be confidently
generalized across many states, especially to their high
poverty neighborhoods. Finally, one may wonder about
the apparent non-significance of geographic place in
these analyses. Are there not critical elements of geog-
raphy that are already well known to be associated with
health care access and effectiveness: urbanity, health care
service endowments, distances to such services and the
like? Surely there are and so, yes, geographic place mat-
ters. Our analysis points out though that the socio-
economic elements of place, particularly the main,
mediating and moderating effects of highly concentrated
impoverishment, probably matters much more.
We think that some of our analyses were statistically
powerful, especially, tests of poverty-health insurance-
colon cancer survival mediation hypotheses that typically
analyzed survival among approximately 3,000 women
and 3,000 men with approximately 1,000 study partici-
pants in each of three poverty groups. Even their unin-
sured subsamples in the range of 250 to 300 probably
ensured detection of important effects. These analyses
tended to provide rather precise effect estimates, engen-
dering substantial scientific and policy confidence.
Admittedly, a few of the moderator hypotheses we
examined, especially those related to the increasingly
specific experiences, for example, of uninsured or under-
insured women or men in high poverty neighborhoods
who were treated optimally for stage III colon cancer,where key subsamples ranged as low as 10 to 25, were
necessarily exploratory. We hope that other researchers,
especially those with access to national cancer data, will
systematically replicate and extend our analyses.
Conclusions
Health insurance substantially mediates the quality of
colon cancer care in the United States. Moreover, pov-
erty seems to make the effects of being uninsured or
underinsured even worse, especially among women.
These findings are consistent with the theory that more
facilitative social and economic capital is available in
more affluent neighborhoods, where people with cancer
may be better able to absorb the indirect and uncovered
direct costs of care. Policy makers need to understand
that even covered health care presently comes with myr-
iad such costs. And though some are able to absorb
them, many others are not.
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